Yineleyen Anjiyoödemin Ender Nedeni: Herediter Anjiyoodem

Herediter anjiyoödem HA ; yineleyen anjiyoödem atakları ile seyreden C1 inhibitör eksikliğine veya fonksiyon bozuk- luğuna bağlı gelişen otozomal dominant kalıtılan bir has- talıktır. Her iki cinste de eşit oranda görülen hastalığın prevalansının 50.000 ila 100.000 doğumda bir olduğu tah- min edilmektedir. Anjiyoödem en sık ekstremiteler, orofa- rinkste ve visseral organlarda görülür. Hastalığın 3 tipi tanımlanmıştır. En sık görülen Tip 1 HA’dir; hastaların %80-85’ini kapsar ve C1 inhibitör düzeyi düşük ve fonksi- yonu bozuktur. HA Tip 2’de ise C1 inhibitör düzeyi normal veya artmış iken, fonksiyonu bozuktur. Son yıllarda, özellik- le gebelerde ve östrojen tedavisi almakta olan kadınlarda Tip 3 HA tanımlanmıştır. Burada yineleyen anjiyoödem ve karın ağrısı ile gelen ve HA Tip 2 tanısı konulan 6 yaşında bir erkek çocuğu sunulmuştur. HA tanısından şüphelenildi- ğinde, C1INH düzeyi normal bulunduğunda C1INH fonksi- yonunun da ölçülmesi önemlidir

Hereditary Angioedema: A Rare Cause of Recurrent Angioedema

Hereditary angioedema HA is a rare, autosomal-dominant genetic disorder presenting with recurrent attacks of angi- oedema which develop secondary deficiency of CI inhibi- tors or related dysfunction. Men and women are equally affected. The prevalence of HA is predicted to be 1 per 50,000 to 150,000 in the general population. The most commonly involved organs include the extremites, face, neck, upper respiratory tract, genital region and the gast- rointestinal tract. There are 3 types of HAE. Type I HA is defined by low plasma levels of a normal C1-INH protein. Type II HA is characterized by the presence of normal or elevated levels of a dysfunctional C1-INH. Type III HA has been recently identified as an estrogen-dependent inherited form of angioedema occurring mainly in women. Herein, a 6-year-old boy who presented with recurrent episodes of angioedema and abdominal pain and diagnosed with type II HA is reported. It is important to highlight the measure- ment of C1INH function in patients with suspect but with normal C1INH levels

___

  • 1. Agostoni A, Cicardi M. Hereditary and acquired C-1 inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992;71(4):206-15. http://dx.doi.org/10.1097/00005792-199207000-00003
  • 2. Bork K, Gül D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007;120:987-92. http://dx.doi.org/10.1016/j.amjmed.2007.08.021
  • 3. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006;26:709-24. http://dx.doi.org/10.1016/j.iac.2006.09.003
  • 4. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 1888;95:362-7. http://dx.doi.org/10.1097/00000441-188804000-00004
  • 5. Frank MM. Hereditary angioedema: a half century of progress. J Allergy Clin Immunol 2004;114:626-8. http://dx.doi.org/10.1016/j.jaci.2004.06.035
  • 6. Fabiani JE, Paulin P, Simkin G, Leoni J, Palombarani S, Squiquera L. Hereditary angioedema: therapeutic effect of danazol on C4 and C1 esterase inhibitors. Ann Allergy 1990; 64:388-2.
  • 7. Witschi A, Krahenbühl L, Frei E, Saltzman J, Spath PJ, Müller UR. Colorectal intussusception: An unusual gastrointestinal complication of hereditary angioedema. Int Arch Allergy Immunol 1996;111:96-8. http://dx.doi.org/10.1159/000237352
  • 8. Zuraw BL. Hereditary angioedema. N Engl J Med 2008;359: 1027-36. http://dx.doi.org/10.1056/NEJMcp0803977
  • 9. Davis AE III. Hereditary angioedema: a current state-of-theart review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008;100(suppl2):S7-12. http://dx.doi.org/10.1016/S1081-1206(10)60580-7
  • 10. Dewald G, Bork K. Missense mutations in the coagulation factor XII gene in hereditary angioedema with normal C1 inhibitor. Biochemical and Biophysical Research Communications 2006;343:1286-9. http://dx.doi.org/10.1016/j.bbrc.2006.03.092
  • 11. Davis AE 3rd: The pathogenesis of hereditary angioedema. Transfus Apher Sci 2003;29:195-203. http://dx.doi.org/10.1016/j.transci.2003.08.012
  • 12. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: consensus document. Exp Immunol 2005;139:379-94.
  • 13. Winnewisser J, Rossi M, Späth P, et al. Type I hereditary angio-oedema: variability of clinical presentation and course within two large kindreds. J Intern Med 1997;241:39-46. http://dx.doi.org/10.1046/j.1365-2796.1997.76893000.x
  • 14. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the diagnosis, therapy, and management of Hereditary angioedema. Ann Allergy Asthma Immunol 2008;100(Suppl 2):S30-40. http://dx.doi.org/10.1016/S1081-1206(10)60584-4
  • 15. Zuraw BL. Hereditary angioedema: a current state-of-the art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 2008;100(Suppl 2):S13-8. http://dx.doi.org/10.1016/S1081-1206(10)60581-9
  • 16. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74. http://dx.doi.org/10.1016/j.amjmed.2005.09.064
  • 17. Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006;26:653-68. http://dx.doi.org/10.1016/j.iac.2006.09.005
  • 18. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009;15:69-78. http://dx.doi.org/10.1016/j.molmed.2008.12.001
  • 19. Quastel M, Harrison R, Cicardi M, et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983;71:1041-6. http://dx.doi.org/10.1172/JCI110831
  • 20. www.aid.org.tr- Herediter anjiyoödem çalışma grubu